EU Cancer Plan: Funding Cuts Threaten Progress & Research

The fight against cancer in Europe faces new headwinds as geopolitical instability and shifting priorities relegate health concerns to a secondary position. While health became a priority for the European Union following the COVID-19 pandemic, recent developments suggest a pullback in funding and focus, potentially impacting cancer research, prevention, and treatment programs.

A Shift in Priorities

In 2021, the European Commission approved the European Cancer Plan, allocating 4 billion euros to combat the disease, which accounts for 25% of all deaths on the continent, despite representing only 10% of the global population. However, global instability and an increased emphasis on defence policies have led to budget cuts and a diminished focus on health initiatives.

Did You Know? Each year, Europe sees approximately three million new cancer diagnoses, resulting in 1.4 million deaths.

The EU4Health program, intended to run from 2021 to 2027, experienced a 20% reduction in funding last year, falling from a planned 5.3 billion euros. Cancer is slated to lose its dedicated funding stream in the next financial framework (2028-2036). The European Commission’s proposal, still awaiting ratification, would integrate health funds into a broader competitiveness fund.

Implications of Reduced Funding

This shift means cancer initiatives will no longer have a guaranteed budget allocation. Funding will depend on broader macroeconomic and geopolitical priorities, requiring projects to demonstrate relevance to areas like competitiveness, innovation, or preparedness to secure financing. This could lead to reduced funding for crucial programs such as standardized European colon and breast cancer screening, population-based cancer registries, and support services for survivors, palliative care, and reintegration into the workforce.

These programs may now compete with funding for industries like defence, and biotechnology. Ramón Reyes, president of the Spanish Association Against Cancer (AECC), highlighted that public funding for cancer research in Spain has increased by 65% in the last five years, raising concerns about the sustainability of this progress if European funding is curtailed.

Expert Insight: The redirection of funds from dedicated health programs to broader economic and security initiatives reflects a challenging trade-off. While addressing geopolitical concerns is vital, diminishing investment in preventative healthcare could have long-term consequences for public health and economic stability.

Nicolás González Casares, a Member of the European Parliament, expressed opposition to the budget cuts and advocated for maintaining minimum funding levels specifically for health. He cautioned that rising pharmaceutical costs for cancer treatment could impact patient access to care, and pointed to concerns regarding the influence of a Euroskeptic commissioner, Olivér Várhelyi.

A Structural Problem

The president of the AECC emphasized that cancer is not a temporary issue, but a structural problem requiring sustained, long-term investment. The Organization for the Cooperation and Economic Development (OECD) has warned that cancer diagnoses have risen by approximately 30% since 2000 and, without significant changes in prevention and healthcare, are projected to increase another 18% between 2022 and 2040.

Preventative measures, particularly lifestyle factors—responsible for 40% of tumors—are crucial. Smoking is a leading cause of cancer-related deaths in Spain, accounting for 50,000 fatalities annually, followed by alcohol consumption, poor diet, and a sedentary lifestyle. Cancer screening programs, such as those for colorectal and breast cancer, are estimated to save 35% and 31% of lives, respectively, but Spain currently lacks a centralized registry to accurately track their impact.

Following a scandal involving cancer screening programs in Andalusia, the Spanish Ministry of Health requested data from regional authorities to establish a unified registry. While data has been collected, it remains disorganized and has not yet been published. The AECC is also collaborating with the International Agency for Research on Cancer (IARC) to develop a similar registry, with preliminary data expected in March.

Frequently Asked Questions

What is the European Cancer Plan?

The European Cancer Plan was approved by the European Commission in 2021 and allocated 4 billion euros to combat cancer, identified as the leading cause of mortality in Europe.

What changes are being made to health funding in the EU?

The EU4Health program experienced a 20% funding cut in the past year, and cancer is set to lose its dedicated funding stream in the next financial framework (2028-2036), with funds being integrated into a broader competitiveness fund.

What are the potential consequences of these funding changes?

Reduced funding could impact programs for cancer screening, research, support services for survivors, and palliative care, as these initiatives compete with other priorities like industry and defence.

As European priorities evolve, the future of cancer care and research remains uncertain. Will the EU reaffirm its commitment to public health, or will cancer prevention and treatment become secondary concerns in a shifting geopolitical landscape?